Skip to content
10-K/A

Annual Report

MusclePharm Corporation

0001493152-22-012093

← back to feed
Filed
May 4, 2022 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 31, 2022 33.39M sh
Shares Diluted FY 2021 · Dec 31, 2021 33.36M sh
Shares Diluted restated FY 2021 · Dec 31, 2020 47.77M sh
Capex FY 2021 · Dec 31, 2021 $2K
Capex FY 2021 · Dec 31, 2020 $4K
Operating Cash Flow FY 2021 · Dec 31, 2021 −$8.04M
Operating Cash Flow FY 2021 · Dec 31, 2020 −$868K
Cash And Equivalents FY 2021 · Dec 31, 2021 $1.22M
Cash And Equivalents FY 2021 · Dec 31, 2020 $2M
Stockholders Equity FY 2021 · Dec 31, 2021 −$32.19M
Stockholders Equity FY 2021 · Dec 31, 2020 −$24.42M
Stockholders Equity FY 2021 · Dec 31, 2019 −$27.95M
Current Liabilities FY 2021 · Dec 31, 2021 $41.08M
Current Liabilities FY 2021 · Dec 31, 2020 $32.01M
Total Liabilities FY 2021 · Dec 31, 2021 $43.4M
Total Liabilities FY 2021 · Dec 31, 2020 $37.42M
Current Assets FY 2021 · Dec 31, 2021 $10.97M
Current Assets FY 2021 · Dec 31, 2020 $11.86M
Total Assets FY 2021 · Dec 31, 2021 $11.21M
Total Assets FY 2021 · Dec 31, 2020 $13M
Eps Diluted FY 2021 · Dec 31, 2021 −$0.39
Eps Diluted restated FY 2021 · Dec 31, 2020 $0.07
Eps Basic FY 2021 · Dec 31, 2021 −$0.39
Eps Basic FY 2021 · Dec 31, 2020 $0.10
Net Income FY 2021 · Dec 31, 2021 −$12.87M
Net Income FY 2021 · Dec 31, 2020 $3.19M
Operating Income FY 2021 · Dec 31, 2021 −$8.91M
Operating Income FY 2021 · Dec 31, 2020 $2.6M
Gross Profit FY 2021 · Dec 31, 2021 $5.37M
Gross Profit FY 2021 · Dec 31, 2020 $19.61M
Cost Of Revenue FY 2021 · Dec 31, 2021 $44.67M
Revenue FY 2021 · Dec 31, 2021 $50.04M
Revenue FY 2021 · Dec 31, 2020 $64.44M
Long Term Debt restated FY 2021 · Dec 31, 2020 $964K